Floatz logo

DYNAMOS

Focal Cortical Dysplasia

GRIN Therapeutics, Inc.Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Focal Cortical Dysplasia cohort.

Asset / SponsorPhaseRating
Everolimus
NYU Langone Health
Phase 2B
Radiprodil
GRIN Therapeutics, Inc.
Phase 1/2CCC
svg103
Sovargen
Phase 1/2CCC
Omeprazole
GRIN Therapeutics, Inc.
Phase 1CC
PHYTONADIONE, (E)-(±)-
GRIN Therapeutics, Inc.
Phase 1CC

View all 11 →

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
MASH - Metabolic Dysfunction-Associated SteatohepatitisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →